Inhibitors of cyclophilins and uses thereof

A method of treating viral pathologies or infections in a patient in need thereof, comprising the step of

• administering to said patient a therapeutically effective amount of a compound of formula (I):
• wherein:
• n is 0, 1 or 2;
• A is CH or N, or A is C and form, together with R1, R2 and CO, a heterocyclyl group comprising from 5 to 20 atoms, possibly substituted;
• X is CO, SO2 or CS,
• R1 is chosen from the group consisting of:
• H, alkyl groups, and aralkyl groups, said alkyl or aralkyl groups being possibly substituted,
• R2 is a group of formula NR3R4 or OR5, wherein:
• R3 and R4 being each independently chosen from:
• H, ORa, alkyl groups, aralkyl groups, and aryl groups, Ra being chosen from the group consisting of:
• H, alkyl groups, aryl groups, and aralkyl groups;
• wherein R3 and R4 may form, together with the nitrogen atom carrying them, a heterocyclyl group comprising from 5 to 20 atoms, possibly substituted,
• R5 is chosen from:
• alkyl groups, aryl groups, and aralkyl groups,
• wherein R5 may form, together with the oxygen atom carrying it, a heterocyclyl group from 5 to 20 atoms, possibly substituted,
• R6 is H or an alkyl group, or may form together with R2 a heterocyclyl group from 20 to 30 atoms, or may form together with R1 a heterocyclyl group from 10 to 30 atoms,
• R7 is chosen from the group consisting of:
• aryl groups, heteroaryl groups, —NHPh, heterocyclyl groups, and alkyl groups;
• wherein when R7 is aryl, heteroaryl or heterocyclyl, it is substituted by at least one NH2 group,
• wherein, when A is N, R1 and R2 may form, together with A and CO, a heterocyclyl group comprising from 5 to 20 atoms, possibly substituted,
• or its pharmaceutically acceptable salts, hydrates or hydrated salts or its polymorphic crystalline structures, racemates, diastereomers or enantiomers.